the fallen angel - second trial...... - 500 Beiträge pro Seite

[enkelchen]

tach -

werde mich wieder verstärkt um die gefallenen Engel der Biotechbranche kümmern.

Diesmal werden aber auch die fundamentalen Daten eine Rolle spielen!

Es reicht also nicht nur ein drawdon von über 50% an einem Handelstag, pipeline und Finanzen spielen ebenso eine Rolle.

Werde dazu hier einiges an Informationen einstellen.


Gerd

[enkelchen]

die Index Werte:

http://www.nasdaq.com/dynamic/nasdaqbiotech_activity.stm

Company Name Symbol
Abraxis BioScience, Inc. ABBI
ACADIA Pharmaceuticals Inc. ACAD
Acorda Therapeutics, Inc. ACOR
Adams Respiratory Therapeutics, Inc. ARXT
Adolor Corporation ADLR
Affymetrix, Inc. AFFX
Albany Molecular Research, Inc. AMRI
Alexion Pharmaceuticals, Inc. ALXN
Alkermes, Inc. ALKS
Allos Therapeutics, Inc. ALTH
Alnylam Pharmaceuticals, Inc. ALNY
Altus Pharmaceuticals Inc. ALTU
Amgen Inc. AMGN
Amylin Pharmaceuticals, Inc. AMLN
Anadys Pharmaceuticals, Inc. ANDS
Angiotech Pharmaceuticals, Inc. ANPI
Antigenics Inc. AGEN
Arena Pharmaceuticals, Inc. ARNA
ARIAD Pharmaceuticals, Inc. ARIA
ArQule, Inc. ARQL
Array BioPharma Inc. ARRY
Aspreva Pharmaceuticals Corporation ASPV
AtheroGenics, Inc. AGIX
Auxilium Pharmaceuticals, Inc. AUXL
AVANIR Pharmaceuticals AVNR
AVI BioPharma, Inc. AVII
Axcan Pharma Inc. AXCA
Barrier Therapeutics, Inc. BTRX
BioCryst Pharmaceuticals, Inc. BCRX
Bioenvision, Inc. BIVN
Biogen Idec Inc BIIB
BioMarin Pharmaceutical Inc. BMRN
Biosite, Inc. BSTE
BioVeris Corporation BIOV
Caliper Life Sciences Inc CALP
Cardiome Pharma Corporation CRME
Celgene Corporation CELG
Cell Genesys, Inc. CEGE
Cell Therapeutics, Inc. CTICD
Cephalon, Inc. CEPH
Cerus Corporation CERS
Coley Pharmaceutical Group, Inc. COLY
CollaGenex Pharmaceuticals, Inc. CGPI
Columbia Laboratories, Inc. CBRX
Crucell NV CRXL
Cubist Pharmaceuticals, Inc. CBST
CuraGen Corporation CRGN
Curis, Inc. CRIS
CV Therapeutics, Inc. CVTX
Cypress Bioscience, Inc. CYPB
Cytokinetics, Incorporated CYTK
deCODE genetics, Inc. DCGN
Dendreon Corporation DNDN
DepoMed, Inc. DEPO
Digene Corporation DIGE
Discovery Laboratories, Inc. DSCO
Diversa Corporation DVSA
Durect Corporation DRRX
Dyax Corp. DYAX
Emisphere Technologies, Inc. EMIS
Encysive Pharmaceuticals Inc ENCY
Endo Pharmaceuticals Holdings Inc. ENDP
Enzon Pharmaceuticals, Inc. ENZN
EPIX Pharmaceuticals, Inc. EPIX
Exelixis, Inc. EXEL
Flamel Technologies S.A. FLML
Gen-Probe Incorporated GPRO
Gene Logic Inc. GLGC
Genitope Corporation GTOP
Genomic Health, Inc. GHDX
Genta Incorporated GNTA
Genzyme Corporation GENZ
Geron Corporation GERN
Gilead Sciences, Inc. GILD
GTx, Inc. GTXI
Harvard Bioscience, Inc. HBIO
Hi-Tech Pharmacal Co., Inc. HITK
Hollis-Eden Pharmaceuticals, Inc. HEPH
Human Genome Sciences, Inc. HGSI
Idenix Pharmaceuticals, Inc. IDIX
Illumina, Inc. ILMN
ImClone Systems Incorporated IMCL
ImmunoGen, Inc. IMGN
Immunomedics, Inc. IMMU
Incyte Corporation INCY
Indevus Pharmaceuticals Inc. IDEV
Inhibitex, Inc. INHX
Inspire Pharmaceuticals, Inc. ISPH
InterMune, Inc. ITMN
Introgen Therapeutics, Inc. INGN
Invitrogen Corporation IVGN
Isis Pharmaceuticals, Inc. ISIS
ISTA Pharmaceuticals, Inc. ISTA
Keryx Biopharmaceuticals, Inc. KERX
Kosan Biosciences Incorporated KOSN
Labopharm Inc. DDSS
Lexicon Genetics Incorporated LEXG
LifeCell Corporation LIFC
Ligand Pharmaceuticals Incorporated LGND
Luminex Corporation LMNX
MannKind Corporation MNKD
Matrixx Initiatives Inc. MTXX
Medarex, Inc. MEDX
Medicines Company (The) MDCO
MedImmune, Inc. MEDI
MGI PHARMA, Inc. MOGN
Millennium Pharmaceuticals, Inc. MLNM
Momenta Pharmaceuticals, Inc. MNTA
Monogram Biosciences, Inc. MGRM
Myriad Genetics, Inc. MYGN
Nabi Biopharmaceuticals NABI
Nastech Pharmaceutical Company, Inc. NSTK
Nektar Therapeutics NKTR
NeoPharm, Inc. NEOL
Neurochem Inc NRMX
Neurocrine Biosciences, Inc. NBIX
NitroMed, Inc. NTMD
Northfield Laboratories Inc. NFLD
Novavax, Inc. NVAX
Noven Pharmaceuticals, Inc. NOVN
NPS Pharmaceuticals, Inc. NPSP
Nuvelo, Inc. NUVO
Omrix Biopharmaceuticals, Inc. OMRI
ONYX Pharmaceuticals, Inc. ONXX
Orchid Cellmark Inc. ORCH
Oscient Pharmaceuticals Corporation OSCI
OSI Pharmaceuticals Inc. OSIP
Pain Therapeutics PTIE
Panacos Pharmaceuticals, Inc. PANC
PDL BioPharma, Inc. PDLI
Penwest Pharmaceuticals Co. PPCO
Perrigo Company PRGO
Pharmacyclics, Inc. PCYC
Pharmion Corporation PHRM
Pozen, Inc. POZN
Progenics Pharmaceuticals Inc. PGNX
Qiagen N.V. QGEN
QLT Inc. QLTI
Regeneron Pharmaceuticals, Inc. REGN
Renovis, Inc. RNVS
Rigel Pharmaceuticals, Inc. RIGL
Salix Pharmaceuticals, Ltd. SLXP
Santarus, Inc. SNTS
Savient Pharmaceuticals Inc SVNT
SciClone Pharmaceuticals, Inc. SCLN
Sciele Pharma, Inc. SCRX
Seattle Genetics, Inc. SGEN
Sepracor Inc. SEPR
Shire plc SHPGY
StemCells, Inc. STEM
SuperGen, Inc. SUPG
Tanox, Inc. TNOX
Techne Corporation TECH
Telik, Inc. TELK
Tercica, Inc. TRCA
Teva Pharmaceutical Industries Limited TEVA
Third Wave Technologies, Inc. TWTI
Threshold Pharmaceuticals, Inc. THLD
Trimeris, Inc. TRMS
United Therapeutics Corporation UTHR
Vertex Pharmaceuticals Incorporated VRTX
ViaCell, Inc. VIAC
ViroPharma Incorporated VPHM
Vivus, Inc. VVUS
XenoPort, Inc. XNPT
XOMA Ltd. XOMA
ZymoGenetics, Inc. ZGEN

[enkelchen]

http://www.fda.gov/oc/advisory/accalendar/2007/default.htm

[enkelchen]

das ist nur der Anfang -
werde in den einzelnen Positionen noch zukaufen.

Es gibt auch noch einige ander Kandidaten...

[enkelchen]

AGIX wird mein erster "Optionsversuch" sein.

Im März kam die Meldung:


AtheroGenics (AGIX) Announces ARISE Phase III Clinical Study Results, Primary Endpoint Not Achieved
03-27-2007 09:34:14 AM
More FDA


AtheroGenics, Inc. (Nasdaq: AGIX) announced the presentation of its Aggressive Reduction of Inflammation Stops Events (ARISE) Phase III clinical study of lead drug candidate, AGI-1067, at the American College of Cardiology's 56th Annual Scientific Session.

While AGI-1067 did not show a difference from placebo in the composite primary endpoint, the study did achieve a number of other important predefined endpoints. These endpoints included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, myocardial infarction (heart attack) and stroke, as well as improvement in the key diabetes parameters of new onset diabetes and glycemic control.

und

AtheroGenics and AstraZeneca End Collaboration Agreement for AGI-1067
Monday April 23, 2:00 am ET


ATLANTA, GA--(MARKET WIRE)--Apr 23, 2007 -- AtheroGenics, Inc. (NasdaqGM:AGIX - News) today reported that AstraZeneca has notified the Company that it is ending their collaboration to develop and commercialize AGI-1067. As a result of this decision, AtheroGenics will reacquire all worldwide rights for AGI-1067 and will continue to develop the compound. AtheroGenics has been meeting with clinical and regulatory experts to discuss the various options for further development of the compound, and the Company expects to announce its strategy in May. As part of the termination provisions of the agreement, AstraZeneca is responsible for providing transition support to AtheroGenics.
ADVERTISEMENT


"Based on our analysis of the data and discussions we've had to date with clinical and regulatory experts, we remain committed to further developing AGI-1067," stated Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "AtheroGenics has the financial resources to continue the development of AGI-1067, and we look forward to providing more detailed plans in the coming weeks."

About AGI-1067

Preliminary data from the ARISE Phase lll clinical study of AGI-1067 was recently presented at the American College of Cardiology 56th Annual Scientific Sessions. While AGI-1067 did not show a difference from placebo in the composite primary endpoint, the study achieved a number of other important predefined endpoints. These endpoints included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, resuscitated cardiac arrest, myocardial infarction (heart attack) and stroke, as well as improvement in the key diabetes parameters of new onset diabetes and glycemic control.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. In addition to AGI-1067, the Company has a clinical-stage development program studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Disclosure Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve significant risks and uncertainties, including summary statements relating to the potential efficacy and safety profile of AGI-1067. These and other statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. Additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. In addition, our forward-looking statements are subject to a number of factors that could cause actual outcomes to differ materially from those expressed or implied in our forward-looking statements, including that the Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including, but not limited to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006. The risk factors regarding AtheroGenics that are included under the caption "Risk Factors" in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006 are specifically incorporated by reference into this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.



Contact:
Contacts:

AtheroGenics, Inc.
Mark P. Colonnese
Chief Financial Officer
678-336-2511
Email Contact

Media Inquiries
Jayme Maniatis
Schwartz Communications, Inc.
781-684-0770 or 508-971-4015
Email Contact

Investor Inquiries
Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
Email Contact



--------------------------------------------------------------------------------

Astra Zeneca ist also raus!
Im Mai werden die Weichen neu gestellt.
Ich werde mir wohl ein paar Optionen Jun call 2,5
ins Depot legen. Preis ca. 0,60$
Rauscht der Kurs in den Keller, weil das Programm
nicht weiter betrieben wird, bin ich praktisch bei 2,50
abgesichert.
Die Option verfällt also wertlos!
Kommt ein positiver Entscheid (was ich mir erhoffe)
ist nach oben keine Gewinngrenze gegeben.

Wie geschrieben, es ist ein Versuch!!!

Grüsse

[enkelchen]

Zukauf: 500 PSDV zu 1,70$

[enkelchen]

http://www.nasdaq.com/asp/quotes_full.asp?mode=&kind=shortin…

Settlement
Date Short
Interest Avg Daily
Share Volume Days
to Cover
Apr. 13, 2007 9,000,216 11,966,996 1.00
Mar. 15, 2007 5,200,987 1,190,653 4.37
Feb. 15, 2007 4,105,905 1,598,900 2.57
Jan. 12, 2007 4,687,231 2,454,884 1.91
Dec. 15, 2006 4,696,256 7,896,629 1.00
Nov. 15, 2006 4,526,982 447,515 10.12
Oct. 13, 2006 5,120,513 456,207 11.22
Sep. 15, 2006 5,576,848 531,912 10.48
Aug. 15, 2006 5,131,142 415,926 12.34
Jul. 14, 2006 5,049,114 394,276 12.81
Jun. 15, 2006 4,846,466 419,731 11.55
May 15, 2006 4,036,383 382,940 10.54

[enkelchen]

Antwort auf Beitrag Nr.: 29.018.945 von enkelchen am 26.04.07 18:41:25

hab NUVO gegen ANPI getauscht.

GTOP versuche ich nach Gapschluss 3,70 zu kriegen -
da hat der CEO bei 3,20 300.000 Stücke gekauft.
Buchwert ca. 2,90

[enkelchen]

Antwort auf Beitrag Nr.: 29.021.835 von enkelchen am 26.04.07 21:35:57

ich glaube nun eine brauchbare Biotech-Einstellung
gefunden zu haben.
Nicht Chartcraft, nicht bullseye, nein die 2% Einstellung.



rechne hier durchaus mit tieferen Kursen, sollte Glaxo abspringen.
Da solche Meldungen aber nicht gehandelt werden können,
weil immer vor-oder nachbörslich, werde ich die Posi weiter vorsichtig ausbauen.
Mit Buchwert 3,35 sollte nach unten nicht all zu viel passieren.
Kommt der Rücksetzer, werde ich auf jeden Fall nachkaufen.
Geht es vorher über die 3,95 wird dann nachgekauft.
Gruss

[enkelchen]

Antwort auf Beitrag Nr.: 29.021.835 von enkelchen am 26.04.07 21:35:57

300 GTOP eingesackt
100 ADLR dazu
500 PSDV zu 1,79 verkauft
(die hole ich mir günstiger wieder)
Depotgewichtung ist so im Moment ausgewogener.

[enkelchen]

zu psvd:

http://www.psivida.com/News/download/ASX/DSMB%20approval%20t…

[enkelchen]

so, hab nun 500ADLR zu Mischkurs 3,67
und mit Verkauf: Option call 5 Oktober zu 0,55 gecovered.

Meint: die Posi ist nun bis 3,12 abgesichert.
Gewinn allerdings damit auf max. 667,75 begrenzt.
Das wären aber bei überschreiten der 5$ Marke auch noch 40%Gewinn.
Man kann halt net alles haben..

alles klar Rolf?!

[enkelchen]

Antwort auf Beitrag Nr.: 29.075.892 von enkelchen am 30.04.07 18:17:24

versuche bei NFLD mal einen bull call spread.

Kauf Option Jun call 2,5 zu 2,75$
Verkauf Opt.Jun call 5,0 zu 1,15$

Breakeven bei Aktienkurs über 4,10$
max Verlust = Kosten für Optionen= -275+115= -160$
max Gewinn =Spread minus Kosten=250-160= 90$

Alle Angaben ohne Gewähr!!
ich übe noch...

[enkelchen]

Antwort auf Beitrag Nr.: 29.075.892 von enkelchen am 30.04.07 18:17:24

covered call GTOP

500 Aktien Mischkurs 3,72$
Verkauf 5Stück call 5 Jan08 zu 1.65$

Breakeven: Aktienkurs 2,07
max Gewinn (bei über Aktienkurs 5$) = (128+165)x5=1450$
max Verlust 1860$

[enkelchen]

Antwort auf Beitrag Nr.: 29.076.843 von enkelchen am 30.04.07 19:38:31

covered call ISPH

Kauf Aktie zu 7,30$
Verkauf call 7,5 JUN zu 0,80

Breakeven 6,50
max Gewinn 100$ pro Kontrakt = 15% vom Kapitaleinsatz in 7 Wochen
max Verlust 650$ pro Kontrakt

wait and see

[enkelchen]

Heads Up, Biotech Investors
By Mike Havrilla
May 1, 2007

http://www.fool.com/investing/high-growth/2007/05/01/a-weekl…

Biotech investors, mark your calendars and update your watch lists with the dates and companies in this report. Major catalysts are coming down the pike for these companies in the form of FDA decisions and reports of clinical trial data. I have put together a list of companies ranging from around $100 million to just over $1 billion in market cap that are expected to be on the move within the next nine months. Some are well known and heavily traded, while others may be new to you and worthy of further investigation.

Dendreon (Nasdaq: DNDN) has a well-known FDA decision deadline of May 15 for its experimental prostate cancer immunotherapy Provenge. An FDA advisory panel recently gave Provenge the thumbs-up, which bodes well for approval, as the FDA tends to follow the recommendations of these panels. Please see my article from last week for my full take on the stock.

EXACT Sciences (Nasdaq: EXAS) will be presenting positive clinical results later this month for its DNA-based, noninvasive stool screening tests for colorectal cancer and inflammatory bowel disease. More importantly, guidelines expected to be revised in the next few months may include the company's test for colorectal cancer screening. I recently wrote an article on EXACT, which you can check out if you'd like more information on this small-cap company.

Neurochem (Nasdaq: NRMX) is expected to release top-line results for its experimental Alzheimer's drug, Alzhemed, between now and the end of the quarter. The company most recently announced adjustments to the statistical model for this trial that were consistent with previous discussions with the FDA. However, investor pessimism and analyst downgrades over inability to partner Alzhemed prior to trial results have sent shares down about 40% year to date and 20% in the last month alone.

The Fool's CAPS community is not optimistic about Neurochem's prospects. The stock has a lowly one-star rating and bears outnumber the bulls by a two-to-one margin.

Pozen (Nasdaq: POZN) expects to receive an FDA decision for its combination migraine drug, Trexima, by Aug. 1, following several delays over the past year that required the company to submit additional information. Trexima is a combination of existing drugs naproxen and sumatriptan (Imitrex is the brand name) that has shown effectiveness versus placebos and both drugs used alone. It appears to have a high likelihood of approval and launch by year-end.

Progenics (Nasdaq: PGNX) has an FDA deadline of Jan. 30, 2008, for its subcutaneous injection methylnaltrexone, which treats constipation resulting from use of opiate pain killers. The drug is a modified version of already-marketed naltrexone intended to block the constipating effect while not interfering with pain relief. Progenics and its partner Wyeth have the inside track for this indication since competitor Adolor (Nasdaq: ADLR) reported safety concerns for Entereg last month.

Zymogenetics (Nasdaq: ZGEN) has an FDA decision date of Oct. 18 for its experimental thrombin nasal spray to control bleeding during surgery. The company reported in March that it would not be required to conduct additional trials, saving about 18 months and substantial cash in the development of the highly purified form of thrombin that is not derived from animal or human blood.

Keep in mind this is not meant to be an exhaustive list of all companies in the sector, and I purposely excluded the biggest and most well-known biotech and big pharma companies. My goal is to provide a small selection of companies with a combination of leverage because of their smaller size and a major upcoming catalyst in the way of clinical trial data or FDA decision deadlines. Those two factors can lead to big moves in share prices, which makes these companies worth watching.

Looking for more Foolish biotech coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations and get access to our message boards and exclusive content with a 30-day free trial.

Fool contributor Mike Havrilla, R.Ph., B.S., Pharm.D., is a Rite Aid pharmacist who lives and works in the small Pennsylvania town of Portage. He invites your comments and feedback. Mike does not have a position in any company mentioned here. The Fool has a disclosure policy.

[enkelchen]

wer sich mit Optionen beschäftigen will:

http://www.optionistics.com/f/stock_quotes?op=calendar&symbo…

http://www.schaeffersresearch.com/streetools/options/option_…

http://www.ivolatility.com/data/option_analysis_intro.html

[zenman]

Antwort auf Beitrag Nr.: 29.087.831 von enkelchen am 01.05.07 22:06:51

soviel geld hat me ja gar net
um all die leckerlis zu kaufen

[enkelchen]

Antwort auf Beitrag Nr.: 29.088.046 von zenman am 01.05.07 22:27:22

wenn wir mit den Bios fertisch sind,
bleiben nur noch grüne Wiesen und Auen...

[enkelchen]

Antwort auf Beitrag Nr.: 29.086.478 von enkelchen am 01.05.07 20:29:40

Mein Kaufargument für ISPH:

http://charlotte.bizjournals.com/triangle/stories/2007/04/30…

Inspire shares jump on FDA approval
Triangle Business Journal - 11:58 AM EDT Monday, April 30, 2007
Print this Article Email this Article Reprints RSS Feeds Most Viewed Most Emailed
Inspire Pharmaceuticals' stock price climbed to a 52-week high Monday following the Durham pharmaceutical company's announcement that it has received U.S. regulatory approval to sell a pink-eye treatment.

Inspire said Sunday that the U.S. Food and Drug Administration has OK'd its AzaSite product for commercialization. AzaSite treats bacterial conjunctivitis, a type of pink eye.


The company said it expects to launch the treatment in the latter part of the 2007 third quarter and anticipates the product will generate annual sales of between $30 million and $45 million.

The stock price of Inspire (Nasdaq: ISPH) closed Friday at $7.38 but climbed to $8.70 early Monday, topping its previous 52-week high of $8.29. The company's shares were changing hands at $7.87, up 49 cents, in late morning trading Monday.

[enkelchen]

zu CRGN

Dear XXX,

Thank you for contacting CuraGen Corporation. As we announced this
morning, new clinical results with belinostat, our HDAC inhibitor, will
be presented in June at both the 2007 ASCO Annual Meeting and the 2007
Pan Pacific Lymphoma Conference (press release attached).
---------------------------------------------------------------

Werde mir da einmal einen straddle mit Juli Optionen basis 2,5 basteln.
Bitte als Experiment verstehen!
Mehr ist es noch nicht...

[enkelchen]

Nachkauf PSDV zu 1,60
Mischkurs nun 1,68$

[enkelchen]

alles neu, macht der Mai...
auch bei AGIX?

Astra Zeneca ist raus, aber es scheint, man will nun ohne Hilfe weiter machen:

http://www.atherogenics.com/press/index.html

"The first quarter was highlighted by the reporting of results from our ARISE Phase III clinical trial, which achieved predefined endpoints in important therapeutic areas, such as coronary artery disease and diabetes," stated Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "We believe these positive results support further development of AGI-1067 and we look forward to announcing our strategic plan in May."

überlege mir einen straddle oder ähnliches...

[enkelchen]

Antwort auf Beitrag Nr.: 29.164.099 von enkelchen am 06.05.07 11:35:16

mal ein ganz spontanes Experiment:

Kauf IDMI zu 5,97
Verkauf call Mai 7,5 zu 1,00
Verkauf put Mai 5 zu 1,45

entweder ich hab was auf den Augen, oder
hier gab es gerade eine schöne Chance...

[enkelchen]

Antwort auf Beitrag Nr.: 29.190.574 von enkelchen am 07.05.07 16:45:51

oha, hatte ich auf die Schnelle net gesehen -
da ist noch ein offenes Gap bei ca. 5,50!
Drum Verkauf Aktie zu 6,16
Kauf call zu 1,05
macht einen kleinen Gewinn!
-----------------------

den shortput hab ich aber vergrössert
Mischkurs nun 1,53

[enkelchen]

Antwort auf Beitrag Nr.: 29.191.896 von enkelchen am 07.05.07 17:40:54

das war ein Beispiel, wie man es nicht machen sollte!
FDA Entscheidung steht am 9.Mai an, darum die hohe implizite Vola.
Bin komplett raus -
und solche Schnellschüsse sind in Zukunft tabu!
Für`n Abendessen reicht es aber dennoch....

[enkelchen]

Antwort auf Beitrag Nr.: 29.192.539 von enkelchen am 07.05.07 18:08:48

DNDN im Landeanflug -
hoffentlich hält das Fahrwerk...

[enkelchen]

Antwort auf Beitrag Nr.: 29.231.511 von enkelchen am 09.05.07 14:40:03

spekuliere mal auf einen kleinen Rebound.
Verkauf put 5er DNDN Jun07 zu 0,90 verkauft -
wenn`s blöd läuft, habe ich irgendwann die Aktien zu 4,10$ im Depot...